retatrutide clinical trial safety for weight loss: Study shows 30% body weight loss Phase III retatrutide study demonstrates

Patients with GI sensitivity: While orforglipron's GI side effect profile is broadly similar to injectable GLP-1s, the daily oral dosing means the GI tract is exposed to the active compound on a different kinetic schedule than weekly injections

26, Issue 15, 2025, Article 7239)

"This is not a replacement for trials, but it can move much faster, and that speed matters when a drug goes from niche to mainstream almost overnight." Large Language Models Speed Up Side Effect Detection One major challenge in studying online health discussions has been scale

LDL-C, low-density lipoprotein cholesterol

10.1016/j.nbd.2016.05.011 32 DollS.FreitasF

M., Astrup, A., Wycherley, T